Y Intercept Hong Kong Ltd Buys New Stake in AxoGen, Inc. (NASDAQ:AXGN)

Y Intercept Hong Kong Ltd purchased a new position in AxoGen, Inc. (NASDAQ:AXGN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,285 shares of the medical equipment provider’s stock, valued at approximately $235,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXGN. Creative Planning raised its holdings in shares of AxoGen by 152.2% in the 3rd quarter. Creative Planning now owns 29,790 shares of the medical equipment provider’s stock worth $418,000 after buying an additional 17,980 shares in the last quarter. Sentry Investment Management LLC grew its position in AxoGen by 9.3% in the third quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock valued at $243,000 after acquiring an additional 1,483 shares during the period. Principal Financial Group Inc. acquired a new position in AxoGen during the third quarter worth $207,000. Primoris Wealth Advisors LLC bought a new position in shares of AxoGen during the third quarter valued at $207,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of AxoGen in the 3rd quarter valued at $279,000. Institutional investors own 80.29% of the company’s stock.

AxoGen Stock Down 3.5 %

NASDAQ AXGN opened at $18.62 on Wednesday. The stock’s 50 day simple moving average is $17.79 and its 200 day simple moving average is $15.17. AxoGen, Inc. has a one year low of $5.55 and a one year high of $21.00. The firm has a market cap of $825.69 million, a PE ratio of -58.19 and a beta of 1.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group increased their target price on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.